Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Next Previous
Search
Trial Profile

A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allogeneic mesenchymal stem cells therapy-Bonus BioGroup (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Bonus BioGroup

    • Most Recent Events

    • 20 Feb 2025 According to a Bonus BioGroup media release, company announced that it has received U.S. Food and Drug Administration (FDA) clearance to proceed with a Phase III clinical study in the United States to evaluate the efficacy and safety of MesenCure to treat respiratory distress in hospitalized, severely ill patients resulting from pneumonia related to COVID-19. The IND application is supported, among other factors, by results from a Phase II clinical study of MesenCure completed in 2022.
    • 28 Sep 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2026.
    • 28 Sep 2023 Planned primary completion date changed from 31 Dec 2023 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top